Rein Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Rein Therapeutics, Inc. (RNTX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$8.85 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-04-02
- Rein Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$1.56M, a 109.65% decline year-over-year.
- Rein Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $4.03M, a 551.21% increase year-over-year.
- Rein Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was $16.21M.
- Rein Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was $619.00K.
- Rein Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$8.85M, a 152.23% decline from fiscal 2016.
- Rein Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $16.95M.
- Rein Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$2.44M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $2.47M derived: sum of 2 quarters · filed 2018-04-02 | -$8.85M 10-K · filed 2018-04-02 | |
| 2017-09-30 | $4.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$7.29M 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | -$11.32M 10-Q · filed 2017-08-10 | |||
| 2016-12-31 | $16.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $16.83M derived: sum of 2 quarters · filed 2018-04-02 | $16.95M 10-K · filed 2018-04-02 | |
| 2016-09-30 | $619.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $736.00K 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $117.00K 10-Q · filed 2017-08-10 | |||
| 2015-12-31 | -$2.44M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |